Search

Your selection

Clear all

Filter by content type

Filter by content year

News

Vaxart Provides Business Update and Full Year 2022 Financial Results

March 15, 2023 - … Vaxart Provides Business Update and Full Year 2022 Financial Results Vaxart Provides Business Update and Full Year 2022 Financial Results March 15, 2023 General … COVID-19 vaccine constructs to enhance cross-reactivity and potency with the goal of developing a pan-betacoronavirus …
News

Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers

December 1, 2022 - … in Breastfeeding Mothers December 1, 2022 General Funding and support provided by Bill & Melinda Gates Foundation   … of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants SOUTH SAN … can be challenging. Passive transfer of antibodies from mother to infant that are induced in milk may protect …
News

Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29

November 22, 2022 - … VXRT) today announced that Dr. Sean Tucker , Founder and Chief Scientific Officer, will present at the World … to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart … VXRT) today announced that Dr. Sean Tucker , Founder and Chief Scientific Officer, will present at the World …
News

Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results

November 8, 2022 - … Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results November 8, … quarter with $114.8 million in cash, cash equivalents and marketable securities Conference call today at 4:30 p.m. …
News

Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

September 1, 2022 - … Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine … Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine … September 1, 2022 General —   Study met primary safety and secondary immunogenicity endpoints — — Boosted serum …
News

Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial

August 31, 2022 - … senior management team will host a live conference call and webcast beginning at 8:30 a.m. Eastern Time on the same date to review the data and provide a trial update. Analysts and investors can participate in the conference call by … senior management team will host a live conference call and webcast beginning at 8:30 a.m. Eastern Time on the same …
News

Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results

August 8, 2022 - … Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results August 8, … quarter with $131.5 million in cash, cash equivalents and marketable securities SOUTH SAN FRANCISCO, Calif. , Aug. …
News

New Preclinical Data Demonstrate Two of Vaxart’s COVID-19 Vaccine Candidates Protect Against Omicron

June 3, 2022 - … may be the most effective way to protect against current and future variants,” said Dr. Sean Tucker , Vaxart’s SVP and Chief Scientific Officer. “We developed an Omicron specific vaccine candidate and compared it with our original Wuhan strain vaccine … may be the most effective way to protect against current and future variants,” said Dr. Sean Tucker , Vaxart’s SVP and …
News

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

May 19, 2022 - … in hamsters showed both a decrease in infectious  virus and in transmission Phase 1 data measuring cross-reactivity … other vaccine candidate, the one targeting both the S and N proteins, could be effective against a range of diverse … The study compared various measures of immunity and viral shedding in hamster cohorts immunized with Vaxart’s …
News

Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results

May 9, 2022 - … Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results May 9, 2022 Earnings Data from COVID-19 Phase II study and norovirus Phase IB study are expected in 2022 Ended the 1 …
Scroll to Top